Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-26

FDA Approved: FEBUXOSTAT — Supplemental Application (Hikma Pharmaceuticals USA Inc)

View source ↗

Summary

FDA approved a supplemental application for febuxostat by Hikma Pharmaceuticals USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FEBUXOSTAT (Febuxostat)

Snippet

SUPPL AP for FEBUXOSTAT (FEBUXOSTAT)